Bonum Therapeutics, Inc. filed a Form D with the Securities and Exchange Commission on 2026-04-17.
Bonum Therapeutics, Inc. filed a Form D notice of an exempt securities offering with the SEC on April 17, 2026. The filing reports $26.91M sold. Its industry group is Biotechnology. It names John Mulligan (Executive Officer, Director, Promoter), John McKearn (Director), Monique Schiersing (Director) (SEC Form D, April 17, 2026).
125 companies raised this week.
Companies that just raised money, and the people to call. Before you unlock: the company, the amount, the date and what is inside (for example 2 people, phone, LinkedIn). After: the officers and directors the filing names with their roles, how to reach the company, and a person's email only when we found one.
| Andersen Aggregator LLC | $1.9B | Business services |
| AT Umbrella LLC | $1.9B | Business services |
| Legora, Inc. | $221M | AI and software |
| MD INVESTMENT LLC | $169M | Business services |
| Serval Inc. | $149M | AI and software |
Is this your company?
Sell to companies like Bonum Therapeutics, Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
New Form D on file · 2026-04-17 · the record
Pitching, partnering or investing alongside them? See who really runs and owns Bonum Therapeutics, Inc.
Free to see. No signup.
More on the people and the money behind Bonum Therapeutics, Inc., from the filings we hold.
Biotechnology raises by companies based in Washington, filed within 90 days of this one, largest first.
Get an email when Bonum Therapeutics, Inc. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
We'll show it in your MentionFox inbox when Bonum Therapeutics, Inc. raises, hires or launches. No email unless you switch it on.
Watch Bonum Therapeutics, Inc. →Get the full cited report on Bonum Therapeutics, Inc.
What the filing shows about Bonum Therapeutics, Inc.
Only in the Full Report: Who Runs It, And How To Reach Them · Warning Bells · Who Pays Them, And Who They Are Up Against.
Example from a real report (our sample on Target): “In March 2026, Target announced a planned incremental $1 billion operating investment” Source: Target Corporation (press release)
A Full Report on Bonum Therapeutics, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
The filing gives Bonum Therapeutics, Inc.'s address as 1150 Eastlake Avenue E, Suite 1100, Seattle, WA 98109.
Saved here on this device in the meantime, so nothing is lost either way.
Full funding history for Bonum Therapeutics, Inc. →
This is the company's own disclosure. A payment disclosed on a Form D is a disclosed use of proceeds, not a finding of wrongdoing.
Order the Full Report on Bonum Therapeutics, Inc. See pricing
Bonum Therapeutics, Inc. is a registered filer with the SEC (CIK 1898714) and has filed since 2021-12-22. 3 filings are on record, the latest on 2026-04-17.
A filing shows the company exists and what it reports about itself. It is not an audit or a rating.
Bonum Therapeutics, Inc.'s Form D of 2026-04-17 names John Mulligan, John McKearn, Monique Schiersing and 8 more as its officers, directors or promoters.
Its new offerings report $73.14M sold across 3 offerings, as its own filings state.
Each marker is one filing. The larger marker is the filing this page is about.
Trailing twelve months. 764 filings in Biotechnology, totalled by week. The dot is this raise, $26.91M, on the same scale — one filing against the whole group's total, so it sits low by construction.
John Mulligan is named as Executive Officer and Director and Promoter on the Form D that Bonum Therapeutics, Inc. filed with the SEC on 17 April 2026, one of 11 people that filing names.
John McKearn is named as Director on the Form D that Bonum Therapeutics, Inc. filed with the SEC on 17 April 2026, one of 11 people that filing names.
Monique Schiersing is named as Director on the Form D that Bonum Therapeutics, Inc. filed with the SEC on 17 April 2026, one of 11 people that filing names.
Nicholas Walrod is named as Director on the Form D that Bonum Therapeutics, Inc. filed with the SEC on 17 April 2026, one of 11 people that filing names.
Karl Handelsman is named as Director on the Form D that Bonum Therapeutics, Inc. filed with the SEC on 17 April 2026, one of 11 people that filing names.
Diane Hollenbaugh is named as Executive Officer on the Form D that Bonum Therapeutics, Inc. filed with the SEC on 17 April 2026, one of 11 people that filing names.
Neela Patel is named as Executive Officer on the Form D that Bonum Therapeutics, Inc. filed with the SEC on 17 April 2026, one of 11 people that filing names.
Mitchell Mutz is named as Director on the Form D that Bonum Therapeutics, Inc. filed with the SEC on 17 April 2026, one of 11 people that filing names.
Samuel Bjork is named as Director on the Form D that Bonum Therapeutics, Inc. filed with the SEC on 17 April 2026, one of 11 people that filing names.
Gaurav Aggarwal is named as Director on the Form D that Bonum Therapeutics, Inc. filed with the SEC on 17 April 2026, one of 11 people that filing names.
Samuel Blackman is named as Director on the Form D that Bonum Therapeutics, Inc. filed with the SEC on 17 April 2026, one of 11 people that filing names.
11 people named on the filing — 3 holding an executive role and 8 as directors only.
Named as of the 2026-04-17 filing. Titles and locations are exactly as the filing states — not independently confirmed elsewhere.
No investor is drawn from a Form D — the form states how many invested and never who.
What the filing shows about Bonum Therapeutics, Inc.
Only in the Full Report: Who Runs It, And How To Reach Them · Warning Bells · Who Pays Them, And Who They Are Up Against.
Example from a real report (our sample on Target): “In March 2026, Target announced a planned incremental $1 billion operating investment” Source: Target Corporation (press release)
A Full Report on Bonum Therapeutics, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Bonum Therapeutics, Inc. covers
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
You land back on this company when you are in.
Not ready to upgrade? Keep this one in view instead.
Watchlist Bonum Therapeutics, Inc.You get an alert in MentionFox the next time this company shows up.
If you're behind Bonum Therapeutics, Inc.: the weeks after a raise are watched the same way — by other investors sizing you up, and by founders checking who just got funded. FoxPlug turns your commits, deploys, and releases into that story automatically. GetFoxChat puts a guide on your own site so the people this filing just sent you don't leave after one page.
Sourced from the filing index on sec.gov.
Each opens in a new tab, filled in for Bonum Therapeutics, Inc.. With no account yet, you sign up free and land on the result.
On these lists: Biotech raises in Seattle
Share your raise. This card is drawn from the company's own Form D filing, and sharing needs no account.
https://mentionfox.com/funding/bonum-therapeutics-inc-form-d-26000001